KLOWvsSelank

KLOW is a four-component compounded blend designed to layer four mechanistically distinct healing pathways into a single injection — KPV for anti-inflammatory and immune modulation, BPC-157 for vascular and growth factor signalling, TB-500 for cell migration and cytoskeletal dynamics, and GHK-Cu for collagen synthesis and copper-dependent tissue remodelling.

The theoretical sequencing of action covers the full wound-healing cascade. KPV (a tripeptide derived from alpha-MSH) suppresses inflammatory cytokine production via the melanocortin pathway and downregulates NF-kB signalling, calming acute inflammation without immunosuppressing infection control. BPC-157 then drives the proliferative phase by upregulating VEGF-mediated angiogenesis, activating eNOS for nitric oxide signalling, and recruiting fibroblasts to injury sites. TB-500 (thymosin beta-4) sequesters G-actin monomers to facilitate cell migration, allowing repair cells (endothelial progenitors, fibroblasts, keratinocytes) to physically reach injury sites. GHK-Cu (the copper-binding tripeptide) supports the remodelling phase by activating lysyl oxidase to cross-link new collagen and elastin into properly organised, functional tissue rather than disorganised scar.

The combination has gained significant traction on Reddit and in biohacker communities in 2026, particularly for hair regrowth (where the KPV anti-inflammatory and GHK-Cu hair-follicle effects appear additive), skin quality, and post-injury recovery. As with all multi-peptide compounded blends, no controlled clinical trials exist for KLOW specifically — the rationale is built from each component's individual mechanistic profile rather than direct combination data, and inter-component interactions and cumulative safety remain uncharacterised. KLOW is exclusively a compounded preparation, with formulation and quality control varying meaningfully between compounding pharmacies.

Selank is a synthetic heptapeptide based on the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), with a stabilizing Pro-Gly-Pro extension at the C-terminus that dramatically increases its resistance to aminopeptidase degradation. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it was designed to combine the immune-enhancing effects of tuftsin with anxiolytic and nootropic properties.

The anxiolytic mechanism involves modulation of GABAergic neurotransmission. Selank acts as an allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA in anxiety-related brain regions including the amygdala, hippocampus, and prefrontal cortex. This produces a benzodiazepine-like anxiolytic effect without the sedation, cognitive impairment, or addiction potential associated with benzodiazepines — because Selank modulates rather than directly activates the receptor. Additionally, Selank stabilizes enkephalins (endogenous opioid pentapeptides) by inhibiting enkephalin-degrading enzymes (aminopeptidases and enkephalinase/neprilysin), prolonging their mood-regulating and anxiolytic signaling.

The nootropic effects are mediated through neurotrophic factor upregulation. Selank increases expression of brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex, promoting dendritic branching, synaptic plasticity, and long-term potentiation — the cellular mechanisms underlying memory formation and cognitive flexibility. It also modulates serotonergic (5-HT) metabolism, altering the balance between serotonin and its metabolite 5-HIAA in key brain regions. The immunomodulatory component derives from the tuftsin core: tuftsin naturally activates monocytes and macrophages through specific receptors, enhancing phagocytic activity and modulating IL-6, TNF-α, and other cytokine production. This immune regulation occurs at sub-anxiolytic doses, suggesting it is an independent pharmacological effect. The combined anxiolytic, cognitive-enhancing, and immunomodulatory profile is unique among available peptides.